Plasma-Lyte 148® versUs Saline (PLUS) Study

Fluid administration is a fundamental component of the management of critically ill patients and the choice of fluid is a longstanding issue of debate. Worldwide, 0.9% saline has traditionally been the most widely used resuscitation fluid, however its use is increasingly challenged by evidence that suggests its high chloride content may have clinically important adverse effects.

Design

This study is a prospective, multi-centre, parallel group, concealed, blinded, randomised, controlled trial. The primary endpoint will be death from all causes at 90 days after randomisation.

Methods

8,800 patients will be enrolled at approximately 50 study sites in Australia and New Zealand. Participants will be randomly assigned to receive either Plasma-Lyte 148® or 0.9% saline for all resuscitation episodes and for all compatible crystalloid therapy while in ICU for up to 90 days after the first episode of fluid resuscitation (randomisation).

The George Institute country sites:

Affiliation/s

Social links Global

Acknowledgement of Country

The George Institute acknowledges the Gadigal People of the Eora Nation as the Traditional Custodians of the land on which our Australia office and Global Headquarters are built. We pay our respect to Elders past, present and emerging.